AwardJun 30, 2026, 04:07 PM
Aptevo Secures $1.5M Grant for APVO451 IND-Enabling Studies
AI Summary
Aptevo Therapeutics Inc. secured a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund. This funding will support Investigational New Drug (IND)-enabling studies for APVO451, the company's trispecific antibody candidate for solid tumor indications. The project period is expected to extend through June 2028, with funding provided on a reimbursement basis and subject to milestone achievement.
Key Highlights
- Aptevo received a $1,499,951.00 non-dilutive research grant.
- Funding is from the Andy Hill Cancer Research Endowment (CARE) Fund.
- Grant supports IND-enabling studies for APVO451, a trispecific antibody candidate.
- APVO451 targets solid tumor indications, leveraging nectin-4, CD40, and CD3 engagement.
- The project period is expected to extend through June 2028.
- Funding is on a reimbursement basis, subject to milestones and matching contributions.
- Company aims for APVO451 development candidate selection by year-end 2026.
- IND-enabling studies for APVO451 are planned for Q1 2027.
Price Impact
More from APVO
Corporate Action3h ago
Aptevo Therapeutics Extends Rights Agreement Expiration to Oct 2027, Adjusts Purchase Price
InvestmentAug 13, 4:47 PM
Aptevo Therapeutics Raises $4.5M via Warrant Exercise & PIPE
AGM/EGMJul 31, 4:19 PM
Aptevo Schedules 2026 Annual Meeting; Key Proposals Include Director Elections, Stock Plan